A monoclonal superantibody to respond to future variants of SARS-CoV-2?

It is called S2X259 and its properties may well make it a promising candidate for the prevention and treatment of current and future variants of SARS-CoV-2. Under this somewhat barbaric name hides a “super” monoclonal antibody, capable of having a neutralizing activity against all the viral strains encountered so far, but also vis-à-vis all other human and animal betacoronaviruses, such as SARS-CoV-1.

Isolated from B lymphocytes (white blood cells participating in the adaptive immune response) from a recovering donor by a team of international researchers – including study appeared on July 19 in the review Nature –, its main characteristic is to bind to the virus at a highly conserved site in all variants currently in circulation, including Alpha (identified in UK), Beta (discovered in South Africa), Gamma (first sequenced in Brazil ), but also the Delta variant (the first samples of which were listed in India). It appears that S2X259 is only vulnerable to a single and rare possible mutation of the virus, called G504D, which was only detected in 0.002% of the sequences deposited on the Gisaid platform until May 2021.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.